Ropes & Gray advised Cubist Pharmaceuticals, Inc. in its acquisition by Merck, which agreed to acquire Cubist for $102 per share in cash. The total transaction value, including debt, is approximately $9.5 billion. Cubist, a leading global biopharmaceutical company based in Lexington, Mass., focuses on the research, development and supply of antibiotics to treat infections caused by a broad range of drug-resistant bacteria. The deal was announced Dec. 8.
The Ropes & Gray team included partners Christopher Comeau and Paul Kinsella and associate Zachary Blume.
Source: www.ropesgray.com
